Vimarsana
Biggest News Aggregation in the World

Dr Reddys Q3 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dr Reddys Q3. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dr Reddys Q3 Today - Breaking & Trending Today

Revlimid overdose boosts Dr Reddy's Q3 earnings, but turns brokerages cautious - Vimarsana News

Revlimid overdose boosts Dr Reddy's Q3 earnings, but turns brokerages cautious

Published: January 31, 2024

While Dr Reddy's recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug Revlimid while the base US and India business delivered a subpar performance.

Source: moneycontrol.com
Related Topics:
Motilal Oswal Financial ServicesNuvama Institutional EquitiesPharmaceutical ServicesActive IngredientsDr Reddys LabsUzzing StocksBrokerage ViewsDr Reddys Q3Dr Reddys Q3 ResultsR Reddys Q3 EarningsR Reddys Q3 Results UpdatesR Reddys Q3 Brokerage ViewsR Reddys Q3 Brokerage CallsResults UpdatesStock Market Updates
Dr Reddy's Labs Q3 Preview: Revenue, net profit to record tepid growth on lag in domestic sales - Vimarsana News

Dr Reddy's Labs Q3 Preview: Revenue, net profit to record tepid growth on lag in domestic sales

Published: January 29, 2024

Brokerages believe that DRL's commentary on its US base business and margin trend will remain the key monitorable, especially when the contribution from the generic cancer drug Revlimid is expected to gradually taper off through the coming fiscal.

Source: moneycontrol.com
Related Topics:
Nuvama Institutional EquitiesEris LifesciencesKotak Institutional EquitiesDr Reddys Q3Dr Reddys Q3 ResultsR Reddys Q3 Results UpdatesR Reddys Q3 EarningsR Reddys Q3 Earnings PreviewR Reddys Q3 Earnings Updates